Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
Treatment of metastatic renal cell carcinoma (mRCC) has evolved rapidly over the last two decades as major pathways involved in pathogenesis have been elucidated. These include the vascular endothelial growth factor (VEGF) axis and mammalian target of rapamycin (mTOR). Therapies targeting the VEGF p...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer US
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432793/ |